JustinFrankKlamerusMDMMM

Oncology • Detroit, MI

President, Karmanos Cancer Hospital & Network Associate Center Director

Join to view full profile

Dr. Klamerus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Klamerus' full profile

Already have an account?

Office
4100 John R Street
Detroit, MI 48201
Phone+1 313-576-8664
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2009
Ohio State University HospitalChief Residency, Internal Medicine, 2006 - 2007
Ohio State University HospitalResidency, Internal Medicine, 2003 - 2006
Michigan State University College of Human MedicineClass of 2003

Certifications & Licensure

MI State Medical License 2009 - 2025
MD State Medical License 2008 - 2010
OH State Medical License 2003 - 2008

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

32 citations
Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists
Lauren M. Hamel, Louis A. Penner, Susan Eggly, Robert Chapman, Justin Frank Antoni Klamerus, Michael S. Simon, Sarah C. E. Stanton, Terrance L. Albrecht> ;Journal of Oncology Practice. 2017 Mar 1
25 citations
Critical Shortage of African American Medical Oncologists in the United States.
Lauren M. Hamel, Robert Chapman, Mary Malloy, Susan Eggly, Louis A. Penner, Anthony F. Shields, Michael S. Simon, Justin Frank Antoni Klamerus, Charles A. Schiffer, Te...> ;Journal of Clinical Oncology. 2015 Sep 21
12 citations
Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis
Mohammad Muhsin Chisti, Amine Khachani, Govinda Brahmanday, Justin Frank Antoni Klamerus> ;BMJ Case Reports. 2013 Dec 12
7 citations
Relative dose intensity--improving treatment and outcomes in early-stage breast cancer: a retrospective study.
Deborah A. Griffin, Barbara Penprase, Justin F. Klamerus> ;Oncology Nursing Forum. 2012 Oct 29
24 citations
Geographic Proximity and Racial Disparities in Cancer Clinical Trial Participation
Norma Kanarek, Hua Ling Tsai, Sharon Metzger-Gaud, Dorothy Damron, Alla Guseynova, Justin F. Klamerus, Charles M. Rudin> ;Journal of the National Comprehensive Cancer Network. 2010 Dec 1
33 citations
The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center
Justin F. Klamerus, Suanna S. Bruinooge, Xiaobu Ye, Mandi L. Klamerus, Dorothy Damron, Dina Lansey, John C. Lowery, Luis A. Diaz, Jean G. Ford, Norma Kanarek, Charles ...> ;Clinical Cancer Research. 2010 Dec 15
1 citations
Optimizing the Dose and Schedule of Anti–Vascular Endothelial Growth Factor Antibodies in Non–Small-Cell Lung Cancer
Justin F. Klamerus, Julie R. Brahmer> ;Clinical Lung Cancer. 2008 Mar 1
Join now to see all

Press Mentions

McLaren Greater Lansing Appoints Stein as Chief Nursing OfficerMay 16th, 2023
KSP, McLaren's Specialty Pharmacy, Recognized as a Leader in Performance MeasurementMay 9th, 2023
How AI Is Altering Healthcare in MichiganMarch 16th, 2023
Join now to see all